Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 16, 2024
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD has reached an agreement with the U.S. Securities and Exchange...
Aug 22, 2024Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J., Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...
Mar 21, 2024BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the March 19, 2024 U.S. Food and Drug Administration...
Feb 27, 2024BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective...
Dec 11, 2023Company Reinforces its Longstanding Commitment to Help Improve Health Equity and Expand Access to Care Among Vulnerable Populations FRANKLIN LAKES, N.J., Dec. 11, 2023 /PRNewswire/ -- BD (Becton,...
Nov 30, 2023BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety...
Nov 20, 2023WASHINGTON, D.C., USA, Nov. 20, 2023 – BD (Becton Dickinson and Company), a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a...
Nov 9, 2023Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis Q4 revenue from base business (which...
Aug 3, 2023Increased manufacturing capacity combined with an expansion from 69 to 92 eligible countries, is expected to enable delivery of more than 320 million doses through 2030 Previously guaranteed...
-
Aug 3, 2023
Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System Revenue of $4.9 billion...
Aug 1, 2023Single Test on BD MAX™ System Identifies and Differentiates Multiple Respiratory Infectious Diseases from One Sample FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...
Jul 21, 2023BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA)...
-
May 4, 2023
BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and...
Feb 8, 2023Single Test on BD MAX™ Molecular Diagnostic System Identifies and Differentiates Multiple Respiratory Infectious Diseases FRANKLIN LAKES, N.J., Feb. 8, 2023 /PRNewswire/ -- BD (Becton, Dickinson...
-
Feb 2, 2023
Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base...
-
Nov 10, 2022
Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4...
Sep 27, 2022Diagnostic Research Center Enables Students to Test and Develop Clinical Workflows to Help Shape Laboratory Performance and Patient Outcomes FRANKLIN LAKES, N.J., Sept. 27, 2022 /PRNewswire/ -- BD...
Sep 26, 2022Research Use Only (RUO) assay now globally available for BD MAX™ System FRANKLIN LAKES, N.J., Sept. 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...
-
Sep 13, 2022
BD EffivaxTM Glass Prefillable Syringe Features Enhanced Technology that Builds on Company's Decades of Expertise in the Prefillable Syringe Market and Supports Customers' Manufacturing Needs...
-
Aug 4, 2022
Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as...
Jul 28, 2022Acquisition adds to company's recent growth in high-technology pharmacy solutions and further accelerates the company's commitment to Smart, Connected Care – offering a customizable platform to...
Jul 27, 2022Research Use Only (RUO) assay now available for BD MAX™ System users FRANKLIN LAKES, N.J., July 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...
Jun 30, 2022BD MAX™ Molecular Diagnostic Respiratory Viral Panel CE Marked to IVD Directive FRANKLIN LAKES, N.J., June 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading...
Jun 28, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today unveiled findings from a survey conducted by The Harris...
May 26, 2022Second Test for the BD COR™ MX to be CE Marked to IVD Directive FRANKLIN LAKES, N.J., May 26, 2022 / B3C newswire / -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...
May 12, 2022510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company)...
-
May 5, 2022
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline...
Feb 25, 2022FRANKLIN LAKES, N.J. and INDIANAPOLIS (Feb. 25, 2022) – USA Track & Field and BD, a leading global medical technology company, today announced the extension of BD’s sponsorship through 2022....
Feb 8, 2022Organizations including Superhuman Use BD Veritor™ At-Home COVID-19 Test with the ReturnSafe Platform to Keep Employees Safe at WorkBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee...
-
Feb 3, 2022- Revenue of $5.0 billion declined 6.0% as reported and 5.9% on currency-neutral basis, due to a decline in worldwide COVID-only testing revenues to $185 million from $866 million in the prior year
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. "Our...
Feb 1, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business,...
Jan 11, 2022Joint Effort Will Highlight How Diagnostic Best Practices Can Improve Patient Care, Clinical Practice and Health Care EconomicsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with Pfizer Inc. and global charitable foundation Wellcome to better...
-
Jan 6, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that in the interest of the health and safety of its shareholders, directors, officers,...
Dec 22, 2021Tests now available online through Everly Health and in-store at Winn-Dixie, Harveys Supermarket, and Fresco y MásBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical company, today announced the BD Veritor™ At-Home COVID-19 Test is now available for purchase through Everly Health, a...
-
Dec 21, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Embecta Corp. ("embecta"), the independent, publicly-traded company that will hold...
Dec 21, 2021Advances company's innovation focus on enabling new care settings and accelerating smart connected careBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in...
Dec 6, 2021BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that "embecta" [pronounced em-BECK-tah] will be the name of the independent,...
-
Nov 30, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding testing for the COVID-19 Omicron variant of concern....
-
Nov 16, 2021New facility will expand BD’s capacity to supply the European market with pre-fillable syringes for use in applications such as vaccines and other biologic drugs; add 150 local jobs by 2024.
FRANKLIN LAKES, N.J. (November 16, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, broke ground on a €165 million ($200 million USD)...
Nov 12, 2021- Innovation agenda focuses on advancing human health through smart connected care, new care settings and chronic disease outcomesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will begin its Investor Day at 8 a.m. ET today to share how it plans to leverage the breadth and depth...
Nov 4, 2021- Fourth fiscal quarter revenues of $5.1 billion grew 7.3% on a reported basis or 5.9% on a currency-neutral basis.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021....
Oct 28, 2021BARDA to Invest $24.7 Million for BD to Develop New Tests for Core Labs, Hospitals and Point-of-Care LocationsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced...
Oct 26, 2021- BD Veritor™ At-Home COVID-19 Test is now available for purchase on Amazon.comBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has started to ship the first over-the-counter (OTC) COVID-19 rapid antigen test to...
-
Oct 7, 2021New Manufacturing Lines Will Provide U.S. Government with Priority Access to Hundreds of Millions of Needles and Syringes; Bolster Supply Readiness
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has strengthened the U.S. government's access to safety injection devices through...
Sep 21, 2021BD Offers Digitally Read SARS-CoV-2 Rapid Antigen Test and Optional Turn-key Solution in 'Learn to Return' ProgramBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been selected by the state of Washington as a digitally read, rapid antigen test...
Sep 2, 2021Canaan Facility Produced First-Ever Disposable Syringe; Continues to Enable COVID-19 Vaccination CampaignsCANAAN, Conn. (Sept. 2, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 60th anniversary of its manufacturing facility...
Aug 25, 2021- BD Veritor™ At-Home COVID-19 Test is Over-the-Counter, Rapid Antigen Test Using Scanwell Health Mobile App to Deliver Reliable Results in 15 MinutesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
Aug 10, 2021FRANKLIN LAKES, N.J. (Aug. 10, 2021) — BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health...
Aug 6, 2021VIASURE SARS-CoV-2 Variant Real Time PCR Detection Kit for BD MAX™ System Identifies and Differentiates Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variantsZARAGOZA, SPAIN and FRANKLIN LAKES, N.J. (Aug. 6, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec, today announced the CE...
-
Aug 5, 2021
Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis. On a currency-neutral basis, revenues increased 22.0%. BD's COVID-19 testing revenues were $300 million, including BD...
Aug 5, 2021Reidy Will Join Board of Directors of Planned Diabetes Care SpinoffBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher Reidy, 64, executive vice president, chief financial officer (CFO) and...
-
Jul 12, 2021David F. Melcher to be non-executive chair; Claire Pomeroy, MD, MBA, to be a director
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that David F. Melcher will be non-executive chair of the board of directors, and Claire...
Jun 22, 2021BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2020 Sustainability Report, highlighting significant achievements in environmental,...
Jun 11, 2021USA Swimming, the national governing body for the sport of swimming in the United States, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have...
Jun 8, 2021Company Now Supplying More Than 40 Countries for Pandemic Vaccination CampaignsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling 2 billion...
May 18, 2021New plant will produce drug delivery devices, employ 150 people in 2024 and up to 600 when full operations start in 2030BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will build a €165 million ($200 million USD) high-tech manufacturing facility in the city of...
May 13, 2021BD Onclarity™ HPV Assay CE Marked for Self-Collection; Available on BD Viper™ LT and BD COR™ SystemsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry's first self-collection claim for HPV screening has been CE marked to the...
-
May 6, 2021- Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021....
May 6, 2021Standalone Diabetes Care business expected to leverage position as global leader in insulin delivery and expand presence in large and high-growth diabetes marketBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to...
Apr 27, 2021CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit...
Apr 23, 2021USA Track & Field (USATF) and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have partnered to provide rapid COVID-19 testing for USATF athletes at...
Apr 13, 2021WHO Rapid Communication cites high accuracy for the detection of TB, rifampicin and isoniazid resistance on respiratory samplesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was...
-
Apr 1, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona...
Apr 1, 2021BD Veritor™ Plus System supports return-to-school and return-to-work programs through serial testingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization...
Mar 30, 2021New Test on the BD Veritor™ Plus System Can Detect SARS-CoV-2, Influenza A, Influenza B from Single Patient SampleBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA)...
Mar 17, 2021FRANKLIN LAKES, N.J. (March 17, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S....
Mar 9, 2021Reporting app helps facilitate SARS-CoV-2 testing and result reporting from BD Veritor™ Plus SystemBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement with ImageMover, a software platform that automates and simplifies medical...
-
Feb 22, 2021Aims to Pair BD Antigen Test with Scanwell Health Mobile App
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a...
Feb 12, 2021New single test for the BD MAX™ System also shows ability to detect U.K., South African VariantsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use...
-
Feb 4, 2021- First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31,...
Feb 3, 2021In conjunction with clinical findings and the results of other laboratory testing, BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes may help clinicians determine the risks of Intubation with Mechanical Ventilation and also of mortality in COVID-19 patients, aiding in patient management decisionsEYSINS, Switzerland, (Feb. 3, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark of BD Multitest™ 6-Color TBNK...
Jan 26, 2021Polen to Succeed Vince Forlenza Effective April 28BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of...
Jan 25, 2021Peer-Reviewed Study Suggests BD Antigen Test Likely to Be More Selective at Detecting Patients Who Are Shedding Infectious SARS-CoV-2 VirusBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a peer-reviewed study that shows BD's antigen test may be more...
-
Jan 12, 2021- Preliminary first fiscal quarter 2021 revenues of $5.3 billion grew 25.6% on a reported basis. On a currency-neutral basis, revenues increased 24.2%, driven by higher base revenues in all three segments and COVID diagnostic revenues.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31,...
Dec 16, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1...
-
Dec 14, 2020
FRANKLIN LAKES, N.J. (Dec. 14, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its inaugural cybersecurity annual report,...
-
Nov 24, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter. The dividend...
Nov 23, 2020Reports Generated by BD Synapsys™ 3.84 Informatics Solution Simplify Mandatory Public Health ReportingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be...
Nov 10, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
-
Nov 5, 2020- Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30,...
Nov 2, 2020The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor™ Plus System to be delivered in The Netherlands by mid-NovemberBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid,...
Oct 22, 2020Patrick Kaltenbach appointed chief technology officer
Dave Hickey promoted to president, Life Sciences segmentBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology...
Oct 21, 2020CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR...
Oct 16, 2020BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes brings time-tested immune assessment solution to European clinicians treating COVID-19 patientsEYSINS, Switzerland, Oct. 16, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark and European availability of a...
Oct 7, 2020Global Mercy will deliver free, world-class surgical care to patients in African nations who lack healthcare accessBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, this year celebrates its 25 year of philanthropic partnership with the global nonprofit, Mercy Ships,...
Sep 30, 2020SARS-CoV-2 Assay for BD Veritor™ Plus System to be available in Europe by end of OctoberBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
Sep 15, 2020FRANKLIN LAKES, N.J. (Sept. 15, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD is aware that a...
Sep 9, 2020Results show clinical study design may influence performance estimates and published sensitivity claims of SARS-CoV-2 antigen testsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new research study that demonstrated performance of the BD Veritor™...
Aug 10, 2020BD (NYSE: BDX), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million in monetary grants and product donations over...
-
Aug 6, 2020- As reported, revenues of $3.855 billion decreased 11.4 percent
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020....
Jul 30, 2020Capital investments will enable U.S. manufacturing of 8 million BD Veritor™ brand SARS-CoV-2 tests per monthBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the...
Jul 21, 2020U.S. Orders 140 Million Additional Devices; Canada Orders 37 Million Additional DevicesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional pandemic orders for needles and syringes from the United States and Canada...
Jul 15, 2020Government committed to use of BD Veritor™ Plus System and 15-minute SARS-CoV-2 test kitsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a commitment from the U.S. Department of Health and Human Services (HHS) to purchase BD...
Jul 8, 2020Company Finalizes Initial Pandemic Order for 50 Million Injection Devices to Support Operation Warp Speed Vaccination ProgramBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced...
Jul 6, 2020- Simple new assay leverages more than 25,000 BD Veritor™ instruments already used across the U.S. to immediately increase access to COVID-19 testing in frontline health care settingsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization...
Jul 3, 2020CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), announced a voluntary recall for all CME America BodyGuard® Infusion System Administration Sets (infusion...
Jul 3, 2020First Shipments of Injection Devices Already Arrived in U.K.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of a large pandemic order from the U.K. government for 65 million needles...
-
May 21, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has priced its previously announced registered offerings of $1.5 billion of common stock, par value $1.00 per share, at a...
-
May 19, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $1.5 billion of common stock, par value $1.00 per share, and $1.5 billion of depositary...
May 7, 2020- As reported, revenues of $4.253 billion increased 1.4 percentBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.253 billion for the second fiscal quarter ended March 31, 2020....